Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case.
B-cell lymphoma
Cutaneous lymphoma
Diffuse large B cell lymphoma
FISH
Leg-type lymphoma
Journal
Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
08
2019
accepted:
24
12
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Several types of B-cell lymphomas, including both primary cutaneous lymphomas and systemic lymphomas, may affect the skin, with partially overlapping clinical, morphological and immunohistochemical features. Currently, the World Health Organization (WHO) classification of primary cutaneous B-cell lymphomas does not include diffuse large B-cell lymphomas (DLBCL) and considers leg-type DLBCL the only primary cutaneous DLBCL. Here we report the case of a 72-year-old white woman with a primary cutaneous neoplasm comprised of large cells with round nuclei, irregularly clumped chromatin and one or more inconspicuous nucleoli. The immunohistochemistry demonstrated positivity for CD20 and MUM1, with no significant genetic translocations detected by fluorescence in-situ hybridization. After staging, we considered this neoplasm a primary cutaneous DLBCL with a non-germinal center phenotype, not otherwise specified, inconsistent with a leg-type DLBCL. Because of this view, we underscore the need for greater knowledge of the molecular landscape of B-cell lymphomas in order to reconsider the classification of such neoplasms in the skin.
Identifiants
pubmed: 32258414
doi: 10.1515/med-2020-0018
pii: med-2020-0018
pmc: PMC7101477
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119-125Informations de copyright
© 2020 Antonello Sica et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest Conflict of interest statement: All the authors of the manuscript declare that they have no conflict of interest in connection with this paper.
Références
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):460-467.e2
pubmed: 25052052
Int J Dermatol. 2019 Oct;58(10):e187-e189
pubmed: 31135956
Infez Med. 2013 Dec;21(4):296-301
pubmed: 24335460
Blood. 2005 Oct 1;106(7):2491-7
pubmed: 15947086
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
Hepatology. 2011 Oct;54(4):1487-9
pubmed: 21608002
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Dig Liver Dis. 2012 Jan;44(1):49-54
pubmed: 21885355
Curr Treat Options Oncol. 2017 Jul;18(7):45
pubmed: 28670664
Blood. 2018 Apr 26;131(17):1993
pubmed: 29699996
World J Gastroenterol. 2019 Jul 14;25(26):3299-3312
pubmed: 31341357
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
JAMA Dermatol. 2014 May;150(5):535-41
pubmed: 24647650
Open Med (Wars). 2019 Nov 12;14:757-760
pubmed: 31844674
Oncologist. 2019 Aug;24(8):e720-e729
pubmed: 30552159
Infection. 2013 Feb;41(1):225-9
pubmed: 22855434
Cancer Med. 2016 Oct;5(10):2740-2755
pubmed: 27665744
J Clin Oncol. 2002 Feb 1;20(3):647-55
pubmed: 11821444
Braz J Infect Dis. 2014 Mar-Apr;18(2):164-9
pubmed: 24650995
Br J Dermatol. 2012 Nov;167(5):1118-23
pubmed: 22759204
Am J Hematol. 2018 Nov;93(11):1427-1430
pubmed: 30039522